Screening per il cancro ovarico nelle pazienti anziane (PLCO Screening Trial)
Prova di screening del cancro alla prostata, ai polmoni, al colon-retto e alle ovaie (PLCO).
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.
SECONDARY OBJECTIVES:
I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.
II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.
IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.
OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).
ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.
ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.
Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
After completion of screening, participants are followed up for at least 13 years.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- National Institutes of Health Clinical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Exclusion Criteria:
-
Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
-
Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
-
Individuals with known prior cancer of the colon, rectum, lung, or ovary
- This includes primary or metastatic PLCO cancers
-
Individuals with previous surgical removal of the entire colon or one lung
- Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
-
Individuals who are participating in another cancer screening or cancer primary prevention trial
-
Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.
-
Individuals who are unwilling or unable to sign the informed consent form
-
Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Selezione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Nessun intervento: Control
Participants receive standard medical care. Participants complete a DHQ at baseline. |
|
|
Comparatore attivo: Ovarian Screening
Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial. |
Correlative studies Undergo questionnaire assessments Undergo TVU
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Deaths From All Causes
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Death Rates From All Causes
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Lasso di tempo: One year from screening examination
|
Number of positive screens with complications |
One year from screening examination
|
|
T0 (Baseline) CA-125 Screening Results
Lasso di tempo: T0 (at study entry)
|
Cancer Antigen 125 (CA-125) result. |
T0 (at study entry)
|
|
T0 (Baseline) TVU Screening Results
Lasso di tempo: T0 (at study entry)
|
Transvaginal Ultrasound (TVU) result. |
T0 (at study entry)
|
|
T1 CA-125 Screening Results
Lasso di tempo: T1 (one year after entry)
|
Cancer Antigen 125 (CA-125) result. |
T1 (one year after entry)
|
|
T1 TVU Screening Results
Lasso di tempo: T1 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T1 (one year after entry)
|
|
T2 CA-125 Screening Results
Lasso di tempo: T2 (two years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T2 (two years after entry)
|
|
T2 TVU Screening Results
Lasso di tempo: T2 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T2 (one year after entry)
|
|
T3 CA-125 Screening Results
Lasso di tempo: T3 (three years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T3 (three years after entry)
|
|
T3 TVU Screening Results
Lasso di tempo: T3 (three years after entry)
|
Transvaginal Ultrasound (TVU) result. |
T3 (three years after entry)
|
|
T4 CA-125 Screening Results
Lasso di tempo: T4 (four years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T4 (four years after entry)
|
|
T5 CA-125 Screening Results
Lasso di tempo: T5 (five years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T5 (five years after entry)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Christine D Berg, National Cancer Institute (NCI)
Pubblicazioni e link utili
Pubblicazioni generali
- Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26.
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16.
- Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. BJC Rep. 2025 Nov 19;3(1):81. doi: 10.1038/s44276-025-00195-6.
- Fan Z, Zhang Y, Yao Q, Liu X, Duan H, Liu Y, Sheng C, Lyu Z, Yang L, Song F, Huang Y, Song F. Effects of joint screening for prostate, lung, colorectal, and ovarian cancer - results from a controlled trial. Front Oncol. 2024 Apr 29;14:1322044. doi: 10.3389/fonc.2024.1322044. eCollection 2024.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie genitali, femmina
- Neoplasie delle ghiandole endocrine
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Neoplasie ovariche
- Fenomeni fisici
- Radiazione
- Radiazione, non ionizzante
- Onde ad ultrasuoni
- Suono
- Onde d'urto ad alta energia
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2012-01758
- CDR0000078532
- NCI-P93-0050
- PLCO-1
- NCI-2012-01758 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- PLCO-Ovarian (Altro identificatore: National Cancer Institute)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .